FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

61 letters match. Newest first.

  1. CVS Health

    FDA told CVS Health its unapproved Pink Eye Relief Drops are an illegal new drug made by a manufacturer with serious quality violations.

    High risk
  2. TRP Company, Inc

    FDA warns TRP Company that its homeopathic eye drops and ointments are unapproved new drugs and may be adulterated.

    High risk
  3. OcluMed LLC

    OcluMed sells unapproved eye drops with website claims to treat or prevent cataracts, FDA says.

    High risk
  4. Walgreens Boots Alliance, Inc.

    FDA warned Walgreens over three store-brand eye drops sold as unapproved new drugs and tied to contract manufacturer manufacturing violations.

    High risk
  5. Similasan AG

    Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.

    High risk
  6. K.C. Pharmaceuticals Inc.

    FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.

    High risk
  7. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  8. Pharmedica USA, LLC

    FDA found Pharmedica made ophthalmic and nasal drugs under insanitary conditions without required sterile controls.

    High risk
  9. Sterling Pharmaceutical Services, LLC

    Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.

    High risk
  10. Imprimis Rx LLC

    FDA warns Imprimis Rx over false, misleading promotion of compounded eye drug Pred-Moxi-Brom.

    Low
  11. Hubei Kangzheng Pharmaceutical Co., Ltd.

    FDA warns Hubei Kangzheng over non-sterile ophthalmic drops, CGMP failures, and unapproved/misbranded pi yen chin.

    High risk